SCHEMBL609081

SCHEMBL609081

CCCCOCC(=O)N[C@@H](CCCNC(=N)N[N+](=O)[O-])C(=O)N[C@@H](CC(C)C)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 19/20 0.52
PSMB11 A5LHX3 12/20 0.52
PSMA7 O14818 12/20 0.52
PSMB1 P20618 12/20 0.52
PSMA1 P25786 12/20 0.52
PSMA2 P25787 12/20 0.52
PSMA3 P25788 12/20 0.52
PSMA4 P25789 12/20 0.52
PSMB8 P28062 12/20 0.52
PSMB9 P28065 12/20 0.52
PSMA5 P28066 12/20 0.52
PSMB4 P28070 12/20 0.52
PSMB6 P28072 12/20 0.52
PSMB10 P40306 12/20 0.52
PSMB3 P49720 12/20 0.52
PSMB2 P49721 12/20 0.52
PSMA6 P60900 12/20 0.52
PSMA8 Q8TAA3 12/20 0.52
PSMB7 Q99436 12/20 0.52
PSMD11 O00231 11/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12754250 0.94 PSMB5 (0.52) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL608381 0.94 PSMB5 (0.53) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL12754251 0.94 PSMB5 (0.51) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL1478862 0.92 PSMB5 (0.52) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL606523 0.92 PSMB5 (0.53) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL1478252 0.91 PSMB5 (0.52) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL12754265 0.91 PSMB5 (0.50) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL607053 0.90 PSMB5 (0.52) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL608448 0.90 PSMB5 (0.52) PSMB5PSMB11PSMA7PSMB1PSMA1
SCHEMBL607074 0.90 PSMB5 (0.52) PSMB5PSMB11PSMA7PSMB1PSMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-8546608-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2013-10-01 US disclosed
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2012-02-16 US disclosed
US-8058262-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-11-15 US disclosed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSMB11 1/4885PSMA7 21/4885
US-20120041196-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSMB11 1/4885PSMA7 21/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSMB11 1/4885PSMA7 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.